Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

40 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DNA copy number gain at 1q23.3 is associated with poor survival in metastatic bladder cancer

ABSTRACT: This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

ORGANISM(S): Homo sapiens

SUBMITTER: Markus Riester

PROVIDER: E-GEOD-39282 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

DNA copy number gain at 1q23.3 is associated with poor survival in metastatic bladder cancer [Affymetrix]

Project description:Metastatic urothelial carcinoma (UC) of the bladder is associated with multiple somatic copy number alterations (SCNAs). We evaluated SCNAs to identify predictors of poor survival in patients with metastatic UC treated with platinum chemotherapy. We obtained overall survival (OS) and DNA copy number data from UC patients in a Spanish discovery cohort and three validation cohorts. GISTIC was used to identify altered regions, and associations between copy number gains/losses and OS were determined by a Cox proportional hazard model adjusting for performance status and visceral disease The output files of the GISTIC 2.0 software are linked as supplementary files on Series record along with readme.txt file describing the contents of each file/column.

2013-07-07 | E-GEOD-39280 | biostudies-arrayexpress

Identification of nine genomic regions of amplification in bladder cancer, correlation with stage, and potential prognositic and therapeutic value

Project description:We sought to test the hypothesis that ascertainment of genome-wide copy number alterations in bladder cancer may have value for clinical management. We performed a genome wide analysis of 164 bladder cancer samples and 27 bladder cancer cell lines to identify genetic changes associated with disease characteristics. Multiplex inversion probe (MIP) analysis, a newly developed genomic technique, was used to study 80 bladder cancers to identify mutations and copy number changes. Selected amplification events were then analyzed in a validation cohort of 84 bladder cancers by multiplex ligation-dependent probe assay (MLPA). In the MIP analysis, 44 regions of significant copy number change were identified using GISTIC. Nine gene-containing regions of amplification were selected for validation in the second cohort by MLPA. Amplification events at these 9 genomic regions were found to correlate strongly with stage, being seen in only 2 of 23 (9%) Ta grade 1 or 1-2 cancers, in contrast to 31 of 61 (51%) Ta grade 3 and T2 grade 2 cancers, p < 0.001. These observations suggest that analysis of genomic amplification of these 9 regions might serve as a guide for clinical decision making, in terms of management decisions following transurethral resection of bladder cancers. This approach is facilitated by the capability of each of the MIP and MLPA methods to analyze formalin-fixed paraffin-embedded DNA, as done here. Furthermore several of the amplified genes identified here (ERBB2, MDM2, CCND1) render the bladder cancers potentially sensitive to targeted therapy. Copy number profiling was completed for 80 urothelial carcinoma samples using the Affymetrix OncoScan(TM) FFPE Express platform.

2013-04-29 | E-GEOD-44323 | biostudies-arrayexpress

Characterization of novel ovarian tumor cell lines that retain the phenotype of primary tumors [MIP]

Project description:The inability to establish stable cell lines from the vast majority of human tumors has limited the use of in vitro models to study human cancer. Currently available tumor cell lines fail to represent the biological diversity of human tumors. We have developed a cell culture medium that enabled us to routinely establish cell lines from diverse subtypes of ovarian tumors. Importantly, the twenty-five ovarian tumor cell lines described here retain the genomic landscape, histopathology, and molecular features of the original tumors. Furthermore, the molecular profile and drug response of these cell lines correlated with distinct groups of primary tumors with different outcomes. Thus, tumor cell lines derived using this methodology represent a significantly improved new platform to study human tumor biology and treatment. DNA was extracted from 25 OCI (human ovarian cancer) cell lines.

2015-06-16 | E-GEOD-40786 | biostudies-arrayexpress

DNA copy number gain at 1q23.3 is associated with poor survival in metastatic bladder cancer [Agilent]

2013-07-07 | E-GEOD-39281 | biostudies-arrayexpress

Agilent 244A aCGH array for comparison of lung tumor CNA to high-throughput sequencing data

Project description:1 lung tumor was profiled for copy-number alterations with the high-resolution Agilent 244A aCGH Array. One lung tumor sample were assayed on the Agilent Human Genome CGH 244A Microarrays with the intent of comparing the genomic alterations reported by the array platform with those reported by high-thoughput sequencing. Human male genomic DNA (Promega P/N G1471) was used as reference. Individual log2 ratios of background subtracted signal intensities were obtained from the Agilent Feature Extraction software version 9.5. The log2 ratios were centered to a median of zero and the resulting log2 ratio values for each probe were segmented using GLAD. All probes within the genomic bounds of a given GLAD-derived segment were given the mean copy number value of probes within that segment.

2010-05-27 | E-GEOD-20574 | biostudies-arrayexpress

Agilent 244A aCGH array for breast, lung, melanoma, ovary, and prostate

Project description:373 tumors were profiled for copy-number alterations with the high-resolution Agilent 244A aCGH Array. Tumor samples were assayed on Agilent Human Genome CGH 244A Microarrays with the intent of surveying the landscape of genomic alterations in 5 tumor types. Human male genomic DNA (Promega P/N G1471) was used as reference. Individual log2 ratios of background subtracted signal intensities were obtained from the Agilent Feature Extraction software version 9.5. The log2 ratios were centered to a median of zero and the resulting log2 ratio values for each probe were segmented using GLAD. All probes within the genomic bounds of a given GLAD-derived segment were given the mean copy number value of probes within that segment.

2010-07-29 | E-GEOD-20393 | biostudies-arrayexpress

Copy number profiling of 13 IDH1 WT and 8 IDHI mutants newly diagnosed, previously untreated Glioblastoma specimens

Project description:Genomic DNA extracted from tumor samples were profiled on Agilent Human 1X1M aCGH Array Profiling copy number changes of GBM samples

2011-07-19 | E-GEOD-30800 | biostudies-arrayexpress

Characterization of novel ovarian tumor cell lines that retain the phenotype of primary tumors

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-06-16 | E-GEOD-40788 | biostudies-arrayexpress

Comparative genomic hybridization by array of human brain metastases and primary breast carcinomas

Project description:This study comprises arrayCGH data from the University clinic Eppendorf (UKE) in Hamburg. The array platform being used is the VUMC v30 30k Oligo chip

2012-03-08 | E-MTAB-354 | biostudies-arrayexpress

Somatic mutations in Liver Cancer

Project description:Hepatocellular carcinoma tumor samples were profiled for chromsomal copy number changes on Affymterix 100K SNP arrays Analysis of copy number changes in Hepatocellular Carcinoma

2012-01-19 | E-GEOD-34957 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data